Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 1/20 | 0.58 |
| ▸ | BRAF | P15056 | 2/20 | 0.49 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | LSS | P48449 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fezolamine SCHEMBL5783220 | 1.00 | PTGIR (0.58) | PTGIRBRAFMAPK3MAPK1MEN1 | |
| Fezolamine SCHEMBL11491149 | 0.98 | PTGIR (0.57) | PTGIRBRAFMAPK3MAPK1MEN1 | |
| Fezolamine SCHEMBL122599 | 0.90 | PTGIR (0.58) | PTGIRBRAFMAPK3MAPK1MEN1 | |
| Fezolamine SCHEMBL122598 | 0.90 | PTGIR (0.58) | PTGIRBRAFMAPK3MAPK1MEN1 | |
| SCHEMBL11484379 | 0.85 | PTGIR (0.56) | PTGIRBRAFMAPK3MAPK1MEN1 | |
| Hydrochloric Acid SCHEMBL11491105 | 0.84 | PTGIR (0.54) | PTGIRBRAFMAPK3MAPK1MEN1 | |
| SCHEMBL17619688 | 0.84 | PTGIR (0.41) | PTGIRHTR7LSSKDM4E | |
| SCHEMBL1385611 | 0.84 | PTGIR (0.44) | PTGIRBRAFMAPK3MAPK1HTR7 | |
| Hydrochloric Acid SCHEMBL2579363 | 0.82 | PTGIR (0.43) | PTGIRBRAFMAPK3MAPK1HTR7 | |
| SCHEMBL8765676 | 0.81 | PTGIR (0.65) | PTGIRMEN1KMT2APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2090 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4106872-A1 | COMPOSITIONS AND METHODS FOR ASSESSING THE EFFICACY OF INHIBITORS OF NEUROTRANSMITTER TRANSPORTERS | Denovo Biopharma LLC (US) | 2022-12-28 | — | — | EP | claimed |
| WO-2022159507-A1 | COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022159506-A1 | DEUTERATED CANNABIDIOL COMPOUNDS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-20220192993-A1 | DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Willow Bark Brands, Inc. | 2022-06-23 | — | — | US | claimed |
| US-20210060123-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2021-03-04 | — | — | US | claimed |
| WO-2020206205-A1 | DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | WILLOW BARK BRANDS, INC (US) | 2020-10-08 | — | — | WO | claimed |
| US-20180161392-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2018-06-14 | — | — | US | claimed |
| CN-104302326-B | Therapeutic use of P75NTR neurotrophin binding proteins | 利维塞普特有限公司 | 2018-03-30 | — | — | CN | claimed |
| EP-2825208-B1 | P75NTR NEUROTROPHIN BINDING PROTEIN FOR THERAPEUTIC USE | LEVICEPT LTD (GB) | 2017-05-17 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-6495154-B1 | ADMINISTERING ANTIDEPRESSANTS, ADRENERGIC STIMULANTS, SEROTONIN AGONISTS AND ANTAGONISTS AS THERAPEUTIC AGENTS FOR SEXUAL DISORDERS | VIVUS INC. | 2002-12-17 | — | — | US | claimed |
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | VIVUS LLC (F/K/A VIVUS, INC.) | 2002-10-31 | — | — | US | claimed |
| US-6403597-B1 | PRETREATMENT SEXUAL INTERCOURSE | VIVUS, INC. | 2002-06-11 | — | — | US | claimed |
| WO-2002041883-A2 | AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION | VIVUS, INC. (US) | 2002-05-30 | — | — | WO | claimed |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | VIVUS, INC. | 2002-03-28 | — | — | US | claimed |
| US-20020019421-A1 | Compositions and therapy for substance addiction | BIBERMAN RONI (IL) | 2002-02-14 | — | — | US | claimed |
| US-20010008896-A1 | Administration of active agents, including 5-HT receptor agonists and antagonists, to treat premature ejaculation | SMITH WILLIAM L (US) | 2001-07-19 | — | — | US | claimed |
| US-5922341-A | Local administration of pharmacologically active agents to treat premature ejaculation | VIVUS, INCORPORATED (US) | 1999-07-13 | — | — | US | claimed |
| US-4182895-A | ANTIDEPRESSANTS, ANALGESICS | STERLING DRUG INC. (US) | 1980-01-08 | — | — | US | claimed |